Clinical Trials
19
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Radius Pharmaceuticals, Inc.
- Registration Number
- NCT05387798
A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Radius Pharmaceuticals, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT05098509
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Rady Children's Hospital, San Diego, California, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome
- First Posted Date
- 2018-03-08
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Radius Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03458416
- Locations
- 🇺🇸
Institute for Research and Innovation | MultiCare Health System, Tacoma, Washington, United States
A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms
- Conditions
- Infantile Spasm
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Radius Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03421496
- Locations
- 🇺🇸
Nicklaus Children's Hospital, Miami, Florida, United States
🇺🇸Beaumont Children's Hospital, Royal Oak, Michigan, United States
🇺🇸Akron Children's Hospital, Akron, Ohio, United States
Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures
- First Posted Date
- 2017-11-28
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Radius Pharmaceuticals, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT03355300
- Locations
- 🇺🇸
Nicklaus Children's Hospital, Miami, Florida, United States
🇺🇸Pediatric Epilepsy and Neurology Specialists, Tampa, Florida, United States
🇺🇸Clinical Integrative Research Center of Atlanta, Atlanta, Georgia, United States
- Prev
- 1
- 2
- Next